Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

AIM WINNERS & LOSERS: Verici Dx rises; Billington profit plunges

30th Sep 2025 11:18

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Tuesday.

----------

AIM - WINNERS

----------

Eqtec PLC, up 29% at 0.45 pence, 12-month range 1.00p-0.31p. The licensor of syngas technology for conversion of waste into sustainable energy and biofuels rises after reporting results on Monday. Pretax loss narrows to EUR2.1 million in the six months to June 30 from EUR3.2 million the year prior. This is despite a drop in revenue to EUR635,984 from EUR1.4 million. Bottom line benefits from a fall in administrative expenses to EUR1.8 million from EUR2.3 million and lower finance costs of EUR618,950, down from EUR1.5 million. Eqtec says the first half is marked by "setbacks" outside its direct control, with "delays, withdrawals and restructuring among customers and partners slowing the pace of delivery across several projects." Chief Executive David Palumbo comments: "While external headwinds have constrained revenue growth in H1 2025, we have maintained strong gross margins and continued to advance strategically important projects in Europe and the USA. Our ability to validate synthetic fuels production and attract interest from new strategic investors demonstrates the long-term potential of our model."

----------

Verici Dx PLC, up 26% at 0.79p, 12-month range 7.00p-0.48p. The developer of advanced clinical diagnostics for organ transplants says its pretax loss widens to USD3.1 million in the six months to the end of June from USD1.3 million a year ago. Revenue falls 43% to USD1.9 million from USD3.3 million. "We have significantly de-risked the business, achieving all the milestones to enable two validated products to be commercialised. We have in place commercial requirements to support the business: our laboratories and logistical operations are set up, we have all the required regulatory approvals, and we have reimbursement," says CEO Sara Barrington. The company continues to expect to meet expectations for the full year.

----------

AIM - LOSERS

----------

Tissue Regenix Group PLC, down 32% at 14.30p, 12-month range 66.00p-15.00p. The regenerative medical devices firm says revenue fell 6.1% in the six months to the end of June to GBP13.8 million from GBP14.7 million a year ago. The pretax loss widens to USD1.0 million from USD63,000. "Although we have seen a downturn in trading in [the first half], with a resultant impact on our cash position, we remain confident in the underlying business and market opportunities for our leading products and superior technology," said Chief Executive Officer Daniel Lee. The firm says it expects trading and cash to improve in the longer term. Revenue is down as a result of "commercial, regulatory and reimbursement challenges" as revenues for BioRinse were hit by delays in regulatory approval impacting the ability to bring on new customers.

----------

Billington Holdings PLC, down 14% at 280.00p, 12-month range 517.40p-233.00p. The structural steel and construction safety solutions company says earnings are down sharply for the first half of the year. Revenue falls 28% to GBP41.8 million for the six months to the end of June from GBP57.9 million a year prior. Pretax profit plunges 64% to GBP1.7 million from GBP4.6 million. The firm declares no interim dividend, unchanged from the prior year. Billington expects results for 2025 to be below market expectations due to client-led contract delays and the associated timing of profit. It says 2026 remains in line with market expectations. "Following a strong performance by Billington in 2024 it is unfortunate that the market for structural steelwork and the construction industry more widely has, as a result of economic uncertainty and lack of consumer confidence, become increasingly subdued during the first half of 2025," says CEO Mark Smith. "The timing of profit recognition on certain significant contracts, as a consequence of client led project delays, will result in the recognition of margin later than was previously anticipated. We are optimistic that the market will see some recovery in 2026 as stability and increased confidence returns to the sector."

----------

By Michael Hennessey, Alliance News reporter

Comments and questions to [email protected]

Copyright 2025 Alliance News Ltd. All Rights Reserved.


Related Shares:

EqtecVerici DxTissue Regenix GroupBillington
FTSE 100 Latest
Value9,312.31
Change12.47